+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 225 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying progressive prostate and salivary gland cancers to evaluate whether PET scans using two radiotracers, FDG and FDHT, can better detect cancer spread in the body. Preliminary studies showed FDG-PET scans can identify abnormal tumor metabolism and track treatment response through PSA changes. This study extends these methods by including FDHT, which targets androgen receptors and may visualize prostate cancers, and also explores how FDHT accumulation relates to androgen receptor expression in tumor samples. Participants will undergo PET scans with FDHT alone or combined with FDG at baseline, week 4, week 12, and then every 12 weeks during treatment for up to 12 months, with a maximum of 8 scan sets per year and 40 lifetime scan sets. Blood samples may be collected to study FDHT pharmacokinetics, and dynamic scans may be performed if additional pharmacokinetic data is needed. The study assesses radiotracer uptake site-by-site compared to conventional imaging like bone scans, CT, and MRI. During the study, participants will have serial PET imaging and possibly blood draws to monitor radiotracer distribution and metabolism. Researchers will measure FDHT accumulation and its correlation with other imaging and clinical markers at baseline, 4 weeks, 12 weeks, and up to 2 years for some outcomes. The main outcome is to assess FDHT uptake in progressive prostate cancer, along with secondary measures including its relationship with FDG uptake, treatment effects, tumor tissue analyses, and tumor diffusivity. The study is conducted by Memorial Sloan Kettering Cancer Center and aims to improve early assessment of treatment outcomes.

All AgesMALEPhase Not Applicable
7 locations
E

Actively Recruiting

Researchers are evaluating the safety, optimal dose, and effectiveness of a combination treatment involving BNT323 trastuzumab pamirtecan and BNT327 pumitamig in people with advanced breast cancer. This includes patients with hormone receptor-positive or negative, HER2-positive, HER2-low, HER2-ultralow, HER2-null breast cancer, or triple-negative breast cancer. The study is a Phase III, multi-site, open-label trial designed to find the best dose and assess the treatments effects in these groups. The study has two parts. Part 1 involves dose escalation where participants with chemotherapy-pretreated advanced breast cancer receive various dose levels of BNT323 plus BNT327 to determine the recommended Phase 2 dose. Part 2 includes dose optimization and exploratory groups, beginning after Part 1s completion. In Part 2 Cohort 1, participants are randomized into four arms to receive either the combination at the recommended dose, the combination at another dose, BNT323 alone, or BNT327 alone. Other cohorts receive the recommended dose without randomization. Participants will undergo treatment cycles with intravenous infusions of the study drugs and be monitored for safety, side effects, and tumor response for up to 36 months. Assessments include tracking dose-limiting toxicities, adverse events, tumor scans, and response rates. Safety monitoring continues up to 90 days after the last dose. The study aims to provide detailed information on the best dose, safety, and potential benefits of these treatments for advanced breast cancer.

Age: 18Years +All GendersPhase 1Phase 2
81 locations
S

Actively Recruiting

Researchers are evaluating whether a high-fiber plant-based diet HFPBD can improve quality of life for people with clonal hematopoiesis CH. This diet mainly includes plant foods such as fruits, vegetables, nuts, beans, and whole grains. The study measures quality of life using questionnaires and surveys filled out by participants. Participants will be randomly assigned to one of two groups. One group will receive high-fiber plant-based meals delivered to their homes for 12 weeks and have regular phone or video calls with a dietitian every 2 weeks for the first 12 weeks, every 4 weeks from weeks 13 to 24, and every 8 weeks from weeks 25 to 52. The other group will receive usual care with phone calls every 4 weeks for the first 12 weeks and dietitian calls at weeks 13 and 53. During the study, participants will complete quality of life surveys using the EORTC QLQ C30 questionnaire. Assessments include phone or video visits with dietitians, dietary intake monitoring, and adherence to the assigned diet. The main outcome is improvement in quality of life within the first 12 weeks. The total study duration for participants is 52 weeks, with ongoing monitoring and support throughout this time.

Age: 18Years +All GendersPhase Not Applicable
7 locations
D

Actively Recruiting

Researchers are investigating whether a dietary intervention can influence treatment response and quality of life in people with newly diagnosed multiple myeloma undergoing standard induction chemotherapy with daratumumab or isatuximab, lenalidomide, bortezomib, and dexamethasone DRVd. The study aims to assess the effects of diet on quality of life, treatment response, and various disease, microbiome, and immune markers by having participants complete questionnaires and other evaluations. Participants are randomly assigned to one of two groups. One group receives usual care, which includes standard chemotherapy and phone calls every 4 weeks with study staff and a dietitian consultation at the end of chemotherapy. The other group receives an intervention with nutrition counseling and coaching, including biweekly dietitian calls for 12 weeks and high-fiber plant-based frozen meals shipped weekly for 12 weeks. Optional group sessions and text message reminders are also provided. Both groups complete dietary and quality of life surveys during the study. During the study, participants complete questionnaires measuring quality of life and dietary intake. Researchers will evaluate the rate of minimal residual disease negative complete response at one year and compare quality of life improvements between groups. Phone or video calls with dietitians and study staff support participant engagement. The study lasts through four 28-day chemotherapy cycles with follow-up assessments up to one year to monitor treatment and quality of life outcomes.

Age: 18Years +All GendersPhase Not Applicable
7 locations
T

Actively Recruiting

Healthy Volunteer

Researchers are evaluating whether telehealth music therapy can be a practical treatment for cognitive difficulties in adults who have survived blood cancers such as lymphoma, leukemia, or myeloma. The study also examines if music therapy and music education can help improve cognitive function as well as symptoms like anxiety, depression, and fatigue in this population. This pilot trial is exploring these effects in hematologic cancer survivors who experience cancer-related cognitive dysfunction. Participants will be assigned to one of three groups the experimental music therapy MT group, the therapist-attention music education TAME control group, or a wait-list control WLC group receiving usual care. Those in the MT and TAME groups will receive 12 weekly 60-minute sessions, with homework assignments between sessions to reinforce skills and concepts. The WLC group completes assessments during a 24-week wait period and can later choose to receive either the MT or TAME intervention. During the study, participants will complete assessments to measure the feasibility of telehealth music therapy, defined by completing at least 9 of the 12 sessions. Researchers will monitor cognitive function, mood symptoms, and fatigue. Participants must be able to complete study assessments independently and consent in English. The total study duration includes the intervention period and follow-up assessments to evaluate outcomes related to cancer-related cognitive dysfunction.

Age: 18Years +All GendersPhase Not Applicable
7 locations
I

Actively Recruiting

Researchers are observing adults with lung cancer, specifically those planned for pulmonary segmentectomy, to understand outcomes after surgery. The study focuses on patients with clinical Stage I suspected non-small cell lung cancer NSCLC and aims to track disease-free survival over 3 and 5 years following surgery. This international registry collects real-world data to provide insights on this surgical approach. Participants undergo planned pulmonary segmentectomy for primary lung cancer. Patient-reported outcomes will be gathered using the Patient-Reported Outcomes Measurement Information System PROMIS, which evaluates physical function, pain interference, and dyspnea severity through web-based surveys. These assessments occur before surgery, between 2 to 4 weeks after surgery, and again 6 months post-surgery. Throughout the study, participants complete questionnaires at specified intervals to report on their health status. The research team will measure 3-year and 5-year disease-free survival rates following segmentectomy. The study spans several years, with the primary completion date in 2029, allowing long-term monitoring of participant outcomes and health progression.

Age: 18Years +All Genders
20 locations
A

Actively Recruiting

Researchers are collecting detailed information in a registry to better understand various types of mature T-cell and natural killer NK-cell lymphomas. This observational study aims to improve knowledge about these rare blood cancers by creating a comprehensive database that includes clinical information and tumor samples from participants. The study is sponsored by Memorial Sloan Kettering Cancer Center and focuses on multiple specific T-cell lymphoma subtypes as defined by recognized classification guidelines. Participants with confirmed mature T-cell or NK-cell lymphoma may choose to provide optional blood and nail samples for future research and biobanking. The study does not involve experimental treatments but gathers data prospectively from individuals meeting strict diagnostic criteria, including those receiving systemic therapy for certain cutaneous lymphoma types. This approach supports long-term data collection rather than testing new therapies. During the study, participants will have clinical data and tumor specimens collected and recorded. Researchers will track the number of participants contributing to the T-cell Lymphoma Master Repository over a 10-year period. The study involves ongoing follow-up to measure disease status and treatment response, with no direct intervention required. Participation helps build a resource to advance future research and understanding of these lymphomas.

All AgesAll Genders
26 locations
A

Actively Recruiting

Researchers are studying how butyrate levels in stool change after following a plant-based diet for at least 12 weeks in people with monoclonal gammopathy of undetermined significance MGUS or smoldering multiple myeloma SMM. The study compares the effects of a plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo on these butyrate levels. This randomized, placebo-controlled trial is conducted by Memorial Sloan Kettering Cancer Center to explore nutritional interventions in these conditions. Participants will be assigned to one of three groups a plant-based diet group receiving two premade meals daily for 12 weeks a supplement group taking algae omega-3 and curcumin supplements twice daily for 52 weeks or a placebo group receiving inactive supplements twice daily for 25 weeks. The plant-based diet includes low glycemic meals with legumes, vegetables, whole grains, and plant fats, coupled with dietary education and counseling every 4 weeks. During the study, participants will be monitored through stool samples to assess microbiome diversity at 12 weeks. They will receive ongoing dietary support and have access to study staff for questions. The study lasts up to 52 weeks depending on the group, with regular assessments to track adherence, safety, and changes in butyrate levels. The research aims to understand how diet and supplements affect gut health in MGUS and SMM patients.

Age: 18Years +All GendersPhase Not Applicable
8 locations
S

Actively Recruiting

Researchers are evaluating if combining propranolol and etodolac with mind-body resilience training MBRT and music therapy can help women experiencing physiological stress around the time of primary debulking surgery PDS or interval debulking surgery IDS for ovarian cancer. The study compares this combined approach to the standard care, which does not include specific interventions to reduce stress. This trial is designed as a prospective randomized pilot study led by Memorial Sloan Kettering Cancer Center, focusing on stress prevention during surgery for advanced ovarian and related cancers. Participants in the intervention group will receive a combination of mind-body resilience training, music therapy, propranolol, and etodolac both before and after surgery. Propranolol is given at 20 mg twice daily for 21 days, then 10 mg twice daily for 3 days after surgery postoperative days 14-16. Etodolac is administered at 400 mg twice daily for 21 days. Psychological interventions may also be provided postoperatively if needed between days 1 to 7 after surgery. The comparison group will receive usual care without these specific stress-reduction interventions. During the study, participants will be monitored for adherence, including completing over 80% of the bundled interventions by 21 days after surgery. Researchers will assess the effectiveness of the interventions in reducing physiological stress around the time of surgery. Participation involves scheduled surgeries, medication administration, behavioral therapy sessions, and possible psychological support. The total study duration extends up to the primary completion date in June 2027, with follow-up focused on intervention adherence and stress response outcomes.

Age: 18Years +FEMALEPhase Not Applicable
7 locations
R

Actively Recruiting

Researchers are evaluating whether a personalized chemoradiation therapy approach, which may include a lower dose of radiation, is as effective as the standard chemoradiation therapy for people with HPV-positive throat cancer. This study also aims to assess if the lower radiation dose combined with standard chemotherapy results in fewer side effects and how these approaches impact participants quality of life through questionnaires. Participants will receive either a personalized radiation dose based on hypoxia status or the standard radiation dose. Those without hypoxia receive 30 Gy in 2 Gy fractions over 15 days with concurrent standard chemotherapy, while those with hypoxia or in the standard group receive 70 Gy in 2 Gy fractions over 35 days with concurrent chemotherapy. After treatment, a FDG PETCT scan is done around 4 months later to check for persistent disease, with surgery performed if needed, followed by additional standard care. During the study, participants will undergo an FMISO-PET scan during week two of radiation to assess hypoxia. Quality of life will be measured with questionnaires, and overall survival at 2 years is the primary outcome. Participants will be monitored through clinical assessments and imaging during and after treatment. The study is expected to complete by August 2027.

Age: 18Years +All GendersPhase 3
9 locations

1-10 of 225

1